Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors
Open Access
- 30 August 2023
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (9) , 1340
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic approach to diverse malignancies, leading to substantial enhancements in patient prognosis. However, along with their benefits, ICIs also increase the incidence of immune-related adverse events (irAEs). In the present paper, we highlight four cases of carpal tunnel syndrome (CTS) as an uncommon manifestation of toxicity induced by ICIs. Although diagnosed with different malignancies, the patients were undergoing ICI therapy when they developed CTS-consistent side effects accompanied by severe neuropathy. Prompt treatment with corticosteroids, intravenous immunoglobulins, or methotrexate resulted in complete symptomatic relief for all patients. This article therefore emphasizes the importance of recognizing and managing rare adverse events associated with ICI use to ensure optimal patient care.Keywords
This publication has 57 references indexed in Scilit:
- Molecular mechanisms of T cell co-stimulation and co-inhibitionNature Reviews Immunology, 2013
- The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T CellsScience Translational Medicine, 2011
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responsesNature Reviews Immunology, 2011
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- The T-cell-receptor signaling networkJournal of Cell Science, 2009
- Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injuryNeuroscience, 2008
- Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient miceNature Medicine, 2003
- CTLA-4 Regulates Induction of Anergy In VivoImmunity, 2001